

compensation in the range of \$500-\$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. The institution of Dr. Krysko has received research support from Biogen Idec. The institution of Dr. Krysko has received research support from National MS Society.

Spinal Cord Neurosarcoidosis: A Clinical-Radiological Correlation of 39 Cases

Rami Al-Hader, Lonni Schultz, Justin Nofar, Vivek Rai, Mirela Cerghet

Objective

Present radiological and clinical data of spinal cord neurosarcoidosis and response to treatment.

Background

The diagnosis of neurosarcoidosis is challenging. Stern et al. have used histopathological data, clinical scenarios, and response to treatment to propose diagnosis criteria for definite, probable, or possible neurosarcoidosis. There is no definitive confirmatory test except sample biopsy, which is not a preferred test for the central nervous system due to potential complications. MRI studies can help detect nervous system involvement; however, it is neither sensitive nor specific.

Design/Methods

Retrospective analysis with descriptive statistics.

Results

Our cohort consisted of 39 patients with spinal neurosarcoidosis. On MRI, 62% of the patients had a longitudinally extensive intramedullary lesion, 21% had one or multiple patchy intramedullary lesions, 31% had leptomeningeal involvement, and 18% had nerve roots enhancement. The cervical spine was most commonly affected (85%), followed by the thoracic (38%) and lumbar (15%). Thirty-seven patients were treated with oral or IV corticosteroids at first presentation, followed by maintenance with oral steroids and maintenance immunosuppressive agents. The three most used agents were Methotrexate (49%), Azathioprine (31%), and Mycophenolate mofetil (18%). Thirty-four patients had MRIs during follow-up, and twenty-nine patients had documented improvement during follow-up, with a median improvement time on MRI of 10.8 months (95% CI = 6.1 to 17 months). Thirty-one patients had enhancement on MRI at presentation, and 18 (58%) had complete enhancement resolution during follow-up, with a median time for resolution of enhancement of 51.8 months (95% CI = 24.9 to 83.4 months).

Conclusions

The diagnosis of spinal neurosarcoidosis can be challenging; however, we found that resolution of MRI enhancement can require a few years of immunosuppression, which is longer compared to other spinal neuroimmunological pathologies. The current knowledge about the treatment and prognosis of neurosarcoidosis is limited, and there is no FDA medication approved nor clinical trials data regarding the treatment of neurosarcoidosis.

Disclosure: Dr. Al-Hader has nothing to disclose. Dr. Schultz has nothing to disclose. Dr. Nofar has nothing to disclose. Dr. Rai has nothing to disclose. Dr. Cerghet has nothing to disclose.

Serum Autoantibody Lowering by the Anti-FcRn Monoclonal Antibody, Nipocalimab, Correlates With Clinical Improvement in Generalized Myasthenia Gravis Patients

Sindhu Ramchandren, Jeff Guptill, Carlo Antozzi, Vera Bril, Josep Gamez, Sven Meuth, Richard Nowak, Dianna Quan, Maria Teresa Sevilla Mantecon, Leona Ling, Yaowei Zhu, Keith Karcher, Hong Sun

Objective

To evaluate the relationship between clinical improvement in Myasthenia Gravis-Activities of Daily Living (MG-ADL) scores and the pharmacodynamic effects of IgG autoantibody lowering induced by nipocalimab in the Vivacity MG Phase 2 study.

Background

Nipocalimab is a fully human, aglycosylated, effectorless IgG1 anti-FcRn monoclonal antibody that targets the neonatal Fc receptor (FcRn) with high affinity, thereby lowering IgG pathogenic antibodies in autoimmune disease.

Design/Methods

The relationship between the reduction in acetylcholine-receptor (AChR)- and Muscle-Specific-Tyrosine-Kinase (MuSK)- autoantibodies with improvement in MG-ADL scores were explored across the four nipocalimab dose arms in the Vivacity MG Phase 2 Study in generalized myasthenia gravis (gMG) patients.

Results

Of the 68 patients enrolled, 54 were randomized to one of the four nipocalimab dosing arms. 51 (94%) were seropositive for anti-AChR, 3 (6%) for anti-MuSK. Nipocalimab was well-tolerated and achieved substantial, dose-dependent and rapid reductions in serum total IgG, including all IgG subtypes and anti-AChR autoantibodies. These reductions were associated with dose-dependent, durable and rapid MG-ADL responses in all nipocalimab-treated groups. A similar trend in IgG4 reduction was noted, though the sample size of MuSK positive patients was small.

Conclusions

The results support the rapid, dose-dependent and predictable effect of nipocalimab in lowering pathogenic autoantibodies and inducing clinical improvement in patients with gMG. In addition, the close correlation between serum IgG, anti-AChR and clinical response suggest the potential of using serial serum IgG levels as a biomarker in management of gMG patients treated with nipocalimab; this will be tested in the ongoing Phase 3 gMG trial.

Disclosure: Dr. Ramchandren has received personal compensation for serving as an employee of Janssen Pharmaceutical Companies of Johnson & Johnson. Dr. Ramchandren has a non-compensated relationship as a Scientific Advisory Board Member with CMT Research Foundation (CMTRF) that is relevant to AAN interests or activities. Dr. Guptill has received personal compensation in the range of \$500-\$4,999 for serving as a Consultant for Grifols. Dr. Guptill has received personal compensation in the range of \$5,000-\$9,999 for serving as a Consultant for Jacobus. Dr. Guptill has received personal compensation in the range of \$500-\$4,999 for serving as a Consultant for Cabaletta. Dr. Guptill has received personal compensation in the range of \$500-\$4,999 for serving as a Consultant for Regeneron. Dr. Guptill has received personal compensation in the range of \$500-\$4,999 for serving as a Consultant for BD. Dr. Guptill has received personal compensation in the range of \$5,000-\$9,999 for serving as a Consultant for Piedmont Pharmaceuticals. Dr. Guptill has received personal compensation in the range of \$500-\$4,999 for serving as a Consultant for Immunovant. Dr. Guptill has received personal compensation in the range of \$500-\$4,999 for serving as a Consultant for Argenx. Dr. Guptill has received personal compensation in the range of \$500-\$4,999 for serving as a Consultant for Momenta. Dr. Guptill has received personal compensation in the range of \$5,000-\$9,999 for serving as a Consultant for Alexion. Dr. Guptill has received personal compensation in the range of \$500-\$4,999 for serving as a Consultant for Signant. Dr. Guptill has received personal compensation in the range of \$5,000-\$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Immunovant. Dr. Guptill has received personal compensation in the range of \$5,000-\$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Guptill has received personal compensation in the range of \$500-\$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx. Dr. Guptill has received personal compensation in the range of \$500-\$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Momenta. Dr. Guptill has received personal

compensation in the range of \$500-\$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Regeneron. Dr. Guptill has received personal compensation in the range of \$500-\$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Dr. Guptill has received personal compensation in the range of \$500-\$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Toleranzia. Dr. Guptill has received personal compensation in the range of \$500-\$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Takeda. Dr. Guptill has received personal compensation in the range of \$5,000-\$9,999 for serving on a Speakers Bureau for Alexion. The institution of Dr. Guptill has received research support from Momenta. The institution of Dr. Guptill has received research support from Ra Pharma. The institution of Dr. Guptill has received research support from NIH. The institution of Dr. Guptill has received research support from MGFA. The institution of Dr. Guptill has received research support from PCORI. The institution of Dr. Guptill has received research support from Elysium Health. The institution of Dr. Guptill has received research support from Verily. The institution of Dr. Guptill has received research support from UNC. Dr. Guptill has received personal compensation in the range of \$500-\$4,999 for serving as a Study Section Member with NIH. Carlo Antozzi has received personal compensation in the range of \$500-\$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Momenta. Dr. Brill has received personal compensation in the range of \$500-\$4,999 for serving as a Consultant for UCB. Dr. Brill has received personal compensation in the range of \$500-\$4,999 for serving as a Consultant for CSL. Dr. Brill has received personal compensation in the range of \$500-\$4,999 for serving as a Consultant for Alnylam. Dr. Brill has received personal compensation in the range of \$500-\$4,999 for serving as a Consultant for Janssen. Dr. Brill has received personal compensation in the range of \$500-\$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Takeda. Dr. Brill has received personal compensation in the range of \$500-\$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Immunovant. Dr. Brill has received personal compensation in the range of \$500-\$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Brill has received personal compensation in the range of \$5,000-\$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Akcea. Dr. Brill has received personal compensation in the range of \$500-\$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Brill has received personal compensation in the range of \$500-\$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alnylam. Dr. Brill has received personal compensation in the range of \$500-\$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for CSL. Dr. Brill has received personal compensation in the range of \$500-\$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx. The institution of Dr. Brill has received research support from UCB. The institution of Dr. Brill has received research support from Argenx. The institution of Dr. Brill has received research support from Momenta. The institution of Dr. Brill has received research support from Immunovant. The institution of Dr. Brill has received research support from Alexion. The institution of Dr. Brill has received research support from Takeda. Dr. Brill has received intellectual property interests from a discovery or technology relating to health care. The institution of Dr. Gamez has received personal compensation in the range of \$500-\$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for CSL Behring. The institution of Dr. Gamez has received research support from Government of Spain (FIS FEDER). Sven G. Meuth has received personal compensation in the range of \$10,000-\$49,999 for serving as a Consultant for Merck. Sven G. Meuth has received personal compensation in the range of \$10,000-\$49,999 for serving as a Consultant for Novartis. Sven G. Meuth has received personal compensation in the range of \$500-\$4,999 for serving as a Consultant for Almirall. Sven G. Meuth has received personal compensation in the range of \$500-\$4,999 for serving as a Consultant for Genzyme. Sven G. Meuth has received personal compensation in the range of \$500-\$4,999 for serving as a Consultant for Biogen. Sven G. Meuth has received personal compensation in the range of \$500-\$4,999 for serving as a Consultant for TEVA. Sven G. Meuth has received personal compensation in the range of \$0-\$499 for serving as a Consultant for PRMA Consulting. Sven G. Meuth has received personal compensation in the range of \$500-\$4,999 for serving as a Consultant for Roche. Sven G. Meuth has received personal compensation in the range of \$500-\$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Sven G. Meuth has received personal compensation in the range of \$500-\$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Sven G. Meuth has received personal compensation in the range of \$5,000-\$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis.

Sven G. Meuth has received personal compensation in the range of \$10,000-\$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Sven G. Meuth has received personal compensation in the range of \$5,000-\$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Celgene. Sven G. Meuth has received personal compensation in the range of \$500-\$4,999 for serving on a Speakers Bureau for MedDay Pharm. Sven G. Meuth has received personal compensation in the range of \$500-\$4,999 for serving on a Speakers Bureau for NeuroConsil GmbH. Sven G. Meuth has received personal compensation in the range of \$50,000-\$99,999 for serving on a Speakers Bureau for Novartis. Sven G. Meuth has received personal compensation in the range of \$50,000-\$99,999 for serving on a Speakers Bureau for Merck. Sven G. Meuth has received personal compensation in the range of \$50,000-\$99,999 for serving on a Speakers Bureau for Biogen. Sven G. Meuth has received personal compensation in the range of \$5,000-\$9,999 for serving on a Speakers Bureau for Roche. Sven G. Meuth has received personal compensation in the range of \$10,000-\$49,999 for serving on a Speakers Bureau for Sanofi. Sven G. Meuth has received personal compensation in the range of \$500-\$4,999 for serving on a Speakers Bureau for Genzyme. Sven G. Meuth has received personal compensation in the range of \$5,000-\$9,999 for serving on a Speakers Bureau for Ares Trading SA. Sven G. Meuth has received personal compensation in the range of \$10,000-\$49,999 for serving on a Speakers Bureau for TEVA. Sven G. Meuth has received personal compensation in the range of \$500-\$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer. The institution of Sven G. Meuth has received research support from Alexion. The institution of Sven G. Meuth has received research support from Almirall. The institution of Sven G. Meuth has received research support from Amicus Therapeutics. The institution of Sven G. Meuth has received research support from Biogen. The institution of Sven G. Meuth has received research support from Diamed. The institution of Sven G. Meuth has received research support from Fresenius. The institution of Sven G. Meuth has received research support from Merck. The institution of Sven G. Meuth has received research support from Novartis. The institution of Sven G. Meuth has received research support from BfR. The institution of Sven G. Meuth has received research support from DFG. The institution of Sven G. Meuth has received research support from IZKF Munster. Dr. Nowak has received personal compensation in the range of \$500-\$4,999 for serving as a Consultant for Alexion. Dr. Nowak has received personal compensation in the range of \$500-\$4,999 for serving as a Consultant for argenx. Dr. Nowak has received personal compensation in the range of \$500-\$4,999 for serving as a Consultant for Momenta. Dr. Nowak has received personal compensation in the range of \$500-\$4,999 for serving as a Consultant for Immunovant. Dr. Nowak has received personal compensation in the range of \$500-\$4,999 for serving as a Consultant for Cabaletta Bio. Dr. Nowak has received personal compensation in the range of \$500-\$4,999 for serving as a Consultant for Viela Bio. The institution of Dr. Nowak has received research support from Ra Pharma. The institution of Dr. Nowak has received research support from Alexion. The institution of Dr. Nowak has received research support from Momenta. The institution of Dr. Nowak has received research support from Immunovant. Dr. Nowak has received research support from argenx. Dr. Nowak has received research support from Viela Bio. The institution of Dr. Quan has received personal compensation in the range of \$500-\$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alnylam. Dr. Quan has received personal compensation in the range of \$0-\$499 for serving as an officer or member of the Board of Directors for AANEM. The institution of Dr. Quan has received research support from Alnylam. The institution of Dr. Quan has received research support from Pfizer. The institution of Dr. Quan has received research support from Cytokinetics. The institution of Dr. Quan has received research support from Argenx. The institution of Dr. Quan has received research support from Momenta. The institution of Dr. Quan has received research support from Ionis. The institution of Dr. Quan has received research support from Alexion. The institution of Dr. Quan has received research support from VielaBio. The institution of Dr. Quan has received research support from Apellis. Dr. Quan has received publishing royalties from a publication relating to health care. Dr. Quan has received publishing royalties from a publication relating to health care. Dr. Sevilla Mantecon has nothing to disclose. Dr. Ling has received personal compensation for serving as an employee of Janssen Pharmaceuticals (Johnson&Johnson). Dr. Ling has stock in Janssen Pharmaceuticals (Johnson&Johnson). Dr. Ling has received intellectual property interests from a discovery or technology relating to health care. Dr. Ling has received intellectual property interests from a discovery or technology relating to health care. Dr. Zhu has received personal compensation for serving as an employee of Janssen Research & Development, LLC. Mr. Karcher has received personal compensation for serving as an employee of Janssen Research and Development. Mr. Karcher has received stock

or an ownership interest from Johnson & Johnson. Dr. Sun has received personal compensation for serving as an employee of Janssen.

Long-term Safety and Efficacy of Efgartigimod in Patients With Generalized Myasthenia Gravis: Interim Results of the ADAPT+ Study

James Howard, Vera Bril, Tuan Vu, Chafic Karam, Stojan Peric, Jan De Bleeker, Hiroyuki Murai, Andreas Meisel, Said Beydoun, Mamatha Pasnoor, Antonio Guglietta, Peter Ulrichs, Caroline Tjoen, Edward Brauer, Kimiaki Utsugisawa, Jan Verschuuren, Renato Mantegazza

Objective

To evaluate the safety and efficacy of efgartigimod in patients with generalized myasthenia gravis (MG) enrolled in the ADAPT+ long-term extension study.

Background

Treatment with efgartigimod, a human IgG1 antibody Fc-fragment that blocks neonatal Fc receptor, resulted in clinically meaningful improvement (CMI) in MG-specific outcome measures in the ADAPT phase 3 clinical trial. All patients who completed ADAPT were eligible to enroll in its ongoing open-label, 3-year extension study, ADAPT+.

Design/Methods

Efgartigimod (10 mg/kg IV) was administered in cycles of once-weekly infusions for 4 weeks, with subsequent cycles initiated based on clinical evaluation. Efficacy was assessed during each cycle utilizing Myasthenia Gravis Activities of Daily Living (MG-ADL) and Quantitative Myasthenia Gravis (QMG) scales.

Results

Ninety-one percent of ADAPT patients (151/167) entered ADAPT+. As of February 2021, 106 AChR-Ab+ and 33 AChR-Ab- patients had received at least 1 dose of open-label efgartigimod (including 66 ADAPT placebo [PBO] patients). The mean (SD) study duration was 363 (114) days, resulting in 138 patient-years of observation. Similar incidence rates per patient year (IR/PY) of serious adverse events were seen in ADAPT (efgartigimod: 0.11; placebo: 0.29) compared to ADAPT+ (0.25). Five deaths (acute myocardial infarction, COVID-19 pneumonia/septic shock, bacterial pneumonia/MG crisis, malignant lung neoplasm, and unknown [multiple cardiovascular risk factors identified on autopsy]) occurred; none were considered related to efgartigimod by the investigator. AEs were predominantly mild or moderate. CMI was observed in AChR-Ab+ patients during each cycle (up to 10 cycles) at magnitudes comparable to improvements observed at week 3 of cycle 1 (mean[SE] improvements: MG-ADL, $-5.1[0.34]$; QMG, $-4.7[0.41]$). Clinical improvements mirrored maximal reductions in total IgG and AChR-Abs across all cycles.

Conclusions

This analysis suggests the efficacy of long-term treatment with efgartigimod was consistent across multiple cycles. No new safety signals were identified, despite being conducted before vaccine availability during the COVID-19 pandemic.

Disclosure: Dr. Howard has received personal compensation in the range of \$5,000-\$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for argenx BVBA. Dr. Howard has received personal compensation in the range of \$5,000-\$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Regeneron Pharmaceuticals. Dr. Howard has received personal compensation in the range of \$10,000-\$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion Pharmaceuticals. Dr. Howard has received personal compensation in the range of \$500-\$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Immuniviant. Dr. Howard has received personal compensation in the range of \$10,000-\$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ra Pharma (now UCB Biosciences). Dr. Howard has received personal

compensation in the range of \$5,000-\$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Viela Bio (Horizon Therapeutics). Dr. Howard has received personal compensation in the range of \$500-\$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi US. Dr. Howard has stock in General Electric dividends. Dr. Howard has stock in Johnson & Johnson dividends. Dr. Howard has stock in Pfizer dividends. An immediate family member of Dr. Howard has stock in GlaxoSmithKline dividends. The institution of Dr. Howard has received research support from Alexion Pharmaceuticals. The institution of Dr. Howard has received research support from argenx BVBA. The institution of Dr. Howard has received research support from Ra Pharma (now UCB Biosciences). The institution of Dr. Howard has received research support from NIH. The institution of Dr. Howard has received research support from Centers for Disease Control/Research Triangle Institute. The institution of Dr. Howard has received research support from Duke University (DCRI). The institution of Dr. Howard has received research support from Millenium Pharmaceuticals. The institution of Dr. Howard has received research support from Cartesian Therapeutics. Dr. Howard has a non-compensated relationship as a Scientific Advisory Board member, Committee member with Myasthenia Gravis Foundation of America that is relevant to AAN interests or activities. Dr. Howard has a non-compensated relationship as a Committee member with American Assoc Neuromuscular and Electrodiagnostic Medicine that is relevant to AAN interests or activities. Dr. Bril has received personal compensation in the range of \$500-\$4,999 for serving as a Consultant for UCB. Dr. Bril has received personal compensation in the range of \$500-\$4,999 for serving as a Consultant for CSL. Dr. Bril has received personal compensation in the range of \$500-\$4,999 for serving as a Consultant for Alnylam. Dr. Bril has received personal compensation in the range of \$500-\$4,999 for serving as a Consultant for Janssen. Dr. Bril has received personal compensation in the range of \$500-\$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Takeda. Dr. Bril has received personal compensation in the range of \$500-\$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Immunovant. Dr. Bril has received personal compensation in the range of \$500-\$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Bril has received personal compensation in the range of \$5,000-\$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Akcea. Dr. Bril has received personal compensation in the range of \$500-\$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Bril has received personal compensation in the range of \$500-\$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alnylam. Dr. Bril has received personal compensation in the range of \$500-\$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for CSL. Dr. Bril has received personal compensation in the range of \$500-\$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx. The institution of Dr. Bril has received research support from UCB. The institution of Dr. Bril has received research support from Argenx. The institution of Dr. Bril has received research support from Momenta. The institution of Dr. Bril has received research support from Immunovant. The institution of Dr. Bril has received research support from Alexion. The institution of Dr. Bril has received research support from Takeda. Dr. Bril has received intellectual property interests from a discovery or technology relating to health care. Dr. Vu has received personal compensation in the range of \$500-\$4,999 for serving as a Consultant for BPL. Dr. Vu has received personal compensation in the range of \$10,000-\$49,999 for serving as a Consultant for Alexion. Dr. Vu has received personal compensation in the range of \$5,000-\$9,999 for serving as a Consultant for UCB. Dr. Vu has received personal compensation in the range of \$5,000-\$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ARGENX. Dr. Vu has received personal compensation in the range of \$500-\$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for MTPA. Dr. Vu has received personal compensation in the range of \$500-\$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amylyx. Dr. Vu has received personal compensation in the range of \$10,000-\$49,999 for serving on a Speakers Bureau for Alexion. Dr. Vu has received personal compensation in the range of \$10,000-\$49,999 for serving on a Speakers Bureau for CSL Behring. Dr. Vu has received personal compensation in the range of \$5,000-\$9,999 for serving on a Speakers Bureau for Allergan. Dr. Vu has received personal compensation in the range of \$5,000-\$9,999 for serving on a Speakers Bureau for Argenx. The institution of Dr. Vu has received research support from CSL Behring. The institution of Dr. Vu has received research support from Alexion. The institution of Dr. Vu has received research support from RA Pharma/UCB. The institution of Dr. Vu has received research support from Mitsubishi Tanaka. The institution of Dr. Vu has received research support from Mass Gen Hospital/Healy Platform Study. The institution of Dr. Vu has received research support from Amylyx Pharma. The institution of Dr. Vu has received research support from ARGENX. The institution of Dr. Vu has received research support from Alector. The

Neurology®

Spinal Cord Neurosarcoidosis: A Clinical-Radiological Correlation of 39 Cases

Rami Al-Hader, Lonni Schultz, Justin Nofar, et al.

Neurology 2022;99;S35

DOI 10.1212/01.wnl.0000903300.80412.bf

This information is current as of December 5, 2022

Updated Information & Services	including high resolution figures, can be found at: http://n.neurology.org/content/99/23_Supplement_2/S35.1.full
Subspecialty Collections	This article, along with others on similar topics, appears in the following collection(s): Cerebrospinal Fluid http://n.neurology.org/cgi/collection/cerebrospinal_fluid CT http://n.neurology.org/cgi/collection/ct Low pressure syndrome http://n.neurology.org/cgi/collection/low_pressure_syndrome
Permissions & Licensing	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: http://www.neurology.org/about/about_the_journal#permissions
Reprints	Information about ordering reprints can be found online: http://n.neurology.org/subscribers/advertise

Neurology® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright © 2022 American Academy of Neurology. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.

